Zoliflodacin
Brand names: Nuzolvence · Active ingredient: Zoliflodacin
In short: NUZOLVENCE is indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg . To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and oth
What is Zoliflodacin used for?
NUZOLVENCE is indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg .
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and other antibacterial drugs, NUZOLVENCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Zoliflodacin dosage
Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with NUZOLVENCE .
NUZOLVENCE must be mixed with water before administering. Do not mix NUZOLVENCE with other liquids or sprinkle on food. Do not take NUZOLVENCE in the dry form. Administer the entire dose within 15 minutes of mixing. If the dose is not administered within 15 minutes of mixing, a new dose of NUZOLVENCE must be prepared .
The recommended dose of NUZOLVENCE in adults and pediatric patients 12 years of age and older weighing at least 35 kg is 3 grams (g) (one packet) administered as a single dose orally.
See Table 1 for instructions on whether to administer NUZOLVENCE with or without food based on body weight .
Dose of NUZOLVENCE | Body Weight (kg) | Administration of NUZOLVENCE Relative to the Ingestion of Food
3 g administered as a single, oral dose | 35 kg to less than 50 kg | Take on an empty stomach, 1 hour before or 2 hours after food
Greater than or equal to 50 kg | Take with food
NUZOLVENCE must be mixed with water before administering.
Do not mix NUZOLVENCE with other liquids or sprinkle on food.
Accurately measure 60 mL of water into the provided mixing container.
Add the entire contents of one unit-dose packet of NUZOLVENCE to the mixing container and immediately secure the provided lid onto the mixing container. Shake vigorously for at least 60 seconds. Continue to shake until all granules are suspended and there is a uniform suspension.
Once NUZOLVENCE is mixed to achieve a uniform suspension, administer the entire contents of the mixing container immediately.
To ensure the full dose of NUZOLVENCE is consumed, add an additional 60 mL of water to the same mixing container, shake, and administer the entire additional 60 mL of water.
Administer the entire dose within 15 minutes of mixing. If the dose is not administered within 15 minutes of mixing, a new dose of NUZOLVENCE must be prepared.
See the
Instructions for Use
for additional details on the preparation and administration of NUZOLVENCE for oral suspension.
How to take Zoliflodacin — instructions & advice from the label
Advise the patient to read the FDA-approved labeling (Medication Guide and Instructions for Use).
Embryo-Fetal Toxicity: Potential Risk for Pregnant Females
Advise pregnant females about the potential risk to the fetus with maternal exposure to NUZOLVENCE .
Advise females who take NUZOLVENCE during pregnancy that a pregnancy safety study is available to monitor pregnancy outcomes and encourage them to report their pregnancy to Entasis Therapeutics at 1-800-651-3861 .
Embryo-Fetal Toxicity Related to Males with Female Partners of Reproductive Potential
Advise males who receive NUZOLVENCE and have female partners of reproductive potential to use effective contraception for at least 3 months after receiving NUZOLVENCE [see Warnings and Precautions (5.2), Use in Specific Populations (8.3), and Nonclinical Toxicology (13.1)].
Testicular Toxicity and Risks to Male Fertility
Advise males that NUZOLVENCE may cause testicular toxicity and impair male fertility [see Warnings and Precautions (5.3), Use in Specific Populations (8.3), and Nonclinical Toxicology (13.1)]. …
Warnings & precautions
Do not take this medicine if: NUZOLVENCE is contraindicated in:
patients with a known history of hypersensitivity to NUZOLVENCE .
patients who use concomitant moderate or strong CYP3A4 inducers because concomitant use is predicted to result in decreased plasma concentrations of zoliflodacin and may reduce the efficacy of NUZOLVENCE .
Based on data from animal studies, NUZOLVENCE may cause fetal harm when administered to a pregnant female at clinically relevant doses. Reproductive and developmental toxicity studies at AUC exposures 1.6-fold (mice) and 8.5-fold (rats) the maximum recommended human dose (MRHD) of zoliflodacin administered to pregnant rodents during organogenesis resulted in fetal malformations (exencephaly) and increased embryo-fetal loss .
Advise pregnant females about the potential risk to the fetus with maternal exposure to NUZOLVENCE. Avoid use of NUZOLVENCE during pregnancy. Obtain a pregnancy test prior to initiation of treatment with NUZOLVENCE in females of reproductive potential .
Based on data from an animal toxicity study, the risk of early pregnancy loss may be increased in female partners of males treated with NUZOLVENCE. A reduced number of live embryos and increased number of embryonic losses were observed in untreated female rats mated with male rats administered zoliflodacin at exposures approximately 3.9-times the clinical exposure at the MRHD for 4 weeks.
Advise males with female partners of reproductive potential to use effective contraception for at least 3 months after administration of NUZOLVENCE. .
Based on findings from animal studies, NUZOLVENCE may cause testicular toxicity and impair male fertility. …
Zoliflodacin side effects
The following clinically significant adverse reactions are discussed in the Warnings and Precautions section of the labeling:
Hypersensitivity Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 782 patients received a 3 g dose of zoliflodacin across all phases of clinical trials.
The safety of NUZOLVENCE was evaluated in a phase 3, randomized, open-label, active-controlled, multicenter, multinational trial (NCT03959527) (Trial 1). In total, 927 patients with suspected uncomplicated gonorrhea due to N. gonorrhoeae were randomized (2:1) and treated with either a single oral 3 g dose of NUZOLVENCE (N=619) or a combination of a single 500 mg intramuscular dose of ceftriaxone and a single 1 g oral dose of azithromycin (N=308) . Patients were eligible for enrollment if they were ≥12 years old and ≥35 kg. The majority (98%) of patients were adults (≥18 years); 14 patients were 15 to 18 years old: 12/619 (1.9%) in the NUZOLVENCE arm and 2/308 (0.6%) in the ceftriaxone and azithromycin arm. South Africa had the highest proportion of enrolled patients (46%), followed by Thailand (29%), the United States (17%), and the European Union (8%). The majority of patients treated with NUZOLVENCE were male (88%). …
Drug interactions
Moderate and Strong CYP3A4 Inducers
Concomitant use of moderate or strong inducers of CYP3A4 with NUZOLVENCE is contraindicated . Zoliflodacin is a CYP3A4 substrate. Moderate and strong CYP3A4 inducers are predicted to result in decreased plasma concentrations of zoliflodacin and may reduce NUZOLVENCE efficacy .
About this medicine
NUZOLVENCE for oral suspension contains zoliflodacin, an oral spiropyrimidinetrione bacterial type II topoisomerase inhibitor. The chemical name of zoliflodacin is (2R,4S,4aS)-11-Fluoro-1,2,4,4a-tetrahydro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-3-oxazolidinyl]spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5(6H),5'(2'H)-pyrimidine]-2',4',6'(1'H,3'H)-trione. Its molecular formula is C22H22FN5O7 and molecular mass is 487.4 g/mol. Its chemical structure is depicted below.
Each unit dose packet of NUZOLVENCE for oral suspension contains 3 g of zoliflodacin and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, talc, and xanthan gum.
How it works: NUZOLVENCE is an antibacterial drug . The ratio of the unbound plasma zoliflodacin area under the concentration-time curve from time of dosing extrapolated to infinity to the zoliflodacin MIC (fAUC0-inf/MIC) is the best predictor of efficacy based on in vitro models of infection. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4beda35a-21b0-4b34-84ea-be6ea8cae50f. Read the full official label on DailyMed.